Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cognex (CGNX) Stock Price

News articles about Cognex (NASDAQ:CGNX) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cognex earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news stories about the scientific and technical instruments company an impact score of 47.0922321370055 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

CGNX has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Cognex from a “strong-buy” rating to a “sell” rating in a report on Tuesday, January 2nd. BidaskClub cut Cognex from a “buy” rating to a “hold” rating in a report on Friday, January 26th. ValuEngine cut Cognex from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Deutsche Bank set a $80.00 target price on Cognex and gave the stock a “buy” rating in a report on Friday, January 19th. Finally, Northcoast Research raised Cognex from a “neutral” rating to a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $66.92.

Shares of NASDAQ:CGNX traded down $1.05 on Friday, hitting $49.29. The company’s stock had a trading volume of 1,711,255 shares, compared to its average volume of 2,177,699. The stock has a market cap of $8,701.68, a price-to-earnings ratio of 33.99 and a beta of 1.58. Cognex has a 12 month low of $39.74 and a 12 month high of $72.99.

Cognex (NASDAQ:CGNX) last announced its earnings results on Thursday, February 15th. The scientific and technical instruments company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.25 by $0.05. The business had revenue of $180.37 million during the quarter, compared to the consensus estimate of $178.75 million. Cognex had a return on equity of 24.23% and a net margin of 23.69%. Cognex’s revenue was up 39.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.20 earnings per share. equities analysts expect that Cognex will post 1.4 EPS for the current fiscal year.

Cognex declared that its Board of Directors has authorized a stock repurchase program on Thursday, February 15th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the scientific and technical instruments company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

The company also recently announced a quarterly dividend, which was paid on Friday, March 16th. Shareholders of record on Friday, March 2nd were given a $0.045 dividend. This represents a $0.18 annualized dividend and a yield of 0.37%. The ex-dividend date was Thursday, March 1st. Cognex’s payout ratio is currently 12.41%.

In other news, Director Anthony Sun sold 10,000 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $56.49, for a total transaction of $564,900.00. Following the transaction, the director now owns 294,262 shares of the company’s stock, valued at approximately $16,622,860.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cognex-cgnx-stock-price.html.

About Cognex

Cognex Corporation (Cognex) is a provider of machine vision products that capture and analyze visual information in order to automate tasks, primarily in manufacturing processes, where vision is required. The Company operates through the machine vision technology segment. The Company’s machine vision products are used to automate the manufacture and tracking of discrete items, such as mobile phones, aspirin bottles and automobile tires, by locating, identifying, inspecting and measuring them during the manufacturing or distribution process.

Insider Buying and Selling by Quarter for Cognex (NASDAQ:CGNX)

Receive News & Ratings for Cognex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply